Orchid Chemicals and Pharmaceuticals has posted a 2.41 per cent dip (year-on-year) in net profit for the second quarter ended September 30 at Rs 23.43 crore. Net sales (standalone) rose 12 per cent to Rs 412.22 crore over the same period last year.
“Our operational performance continues to tread on a strong path. The business model change that we had initiated post the injectable business transfer to Hospira last year continues to augur well with the several long-term supply contracts entered into with large global players paving the way for continued robust earnings,” said Mr K. Raghavendra Rao, Chairman & Managing Director, Orchid.